Publication Name	World Journal of Diabetes
Manuscript ID	29158
Country	Australia

Received	2016-07-31 12:52
Peer-Review Started	2016-08-01 22:00
To Make the First Decision	2016-10-20 08:40
Return for Revision	2016-10-20 14:37
Revised	2016-11-07 13:23
Second Decision	2017-03-07 15:26
Accepted by Journal Editor-in-Chief	2017-03-07 17:34
Accepted by Company Editor-in-Chief	2017-03-17 14:01
Articles in Press	2017-03-17 14:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-05-09 14:33
Publish the Manuscript Online	2017-05-15 10:13

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Effects of glycaemic management on diabetic kidney disease
Manuscript Source	Invited Manuscript
All Author List	Richard J MacIsaac, George Jerums and Elif I Ekinci
Funding Agency and Grant Number	Funding Agency Grant Number ADS-Sevier Research Grant to MacIsaac RJ
Corresponding Author	Richard J MacIsaac, Professor, BSc(HONS), PhD, MBBS, FRACP, Director, Department of Endocrinology and Diabetes, St Vincent’s Health, PO Box 2900, Fitzroy, Melbourne, Victoria 3065, Australia. r.macisaac@unimelb.edu.au
Key Words	Diabetic nephropathy; Albuminuria; Glucose control; Glomerular filtration rate; Diabetes; Chronic kidney disease; Empagliflozin; Liraglutide; Semaglutide
Core Tip	Tight glucose control has been clearly shown to reduce the incidence of micro- and macroalbuminuria. Evidence is now also emerging to suggest that intensive glucose control can slow glomerular filtration rate loss and possibly progression to end stage kidney disease. Furthermore, empagliflozin which is a glucose lowering agent of the sodium glucose like transporter-2 inhibitor class has been shown to have reno-protective effects over and above those expected from its glucose lowering effects alone. Recent clinical trials have also shown that Liraglutide and Semaglutide, injectable glucose lowering agents which are analogues of human glucagon like peptide-1, reduce progression to macroalbuminuria.
Publish Date	2017-05-15 10:13
Citation	MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. World J Diabetes 2017; 8(5): 172-186
URL	http://www.wjgnet.com/1948-9358/full/v8/i5/172
DOI	http://dx.doi.org/10.4239/wjd.v8.i5.172

Full Article (PDF)	WJD-8-172.pdf
Full Article (Word)	WJD-8-172.doc
Manuscript File	29158-Review.docx
Answering Reviewers	29158-Answering reviewers.pdf
Audio Core Tip	29158-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	29158-Conflict-of-interest statement.pdf
Copyright License Agreement	29158-Copyright assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	29158-Grant application form(s).pdf
Peer-review Report	29158-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	29158-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	29158-Scientific misconduct check.pdf
Scientific Editor Work List	29158-Scientific editor work list.pdf